Overview

NCI Definition: A myelodysplastic syndrome caused by chemotherapy and/or radiotherapy. [1]

Therapy-related myelodysplastic syndromes most frequently harbor alterations in TP53, DNMT3A, TET2, ASXL1, and ZRSR2 [2].

Most Commonly Altered Genes in Therapy-Related Myelodysplastic Syndrome

TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 5 Mutation, and DNMT3A Mutation are the most common alterations in therapy-related myelodysplastic syndrome [2].

Top Alterations in Therapy-Related Myelodysplastic Syndrome

Significant Genes in Therapy-Related Myelodysplastic Syndrome

ABL1 +

AFF1 +

ASXL1 +

BCOR +

BCR +

CBFB +

CBL +

DEK +

DNMT3A +

ELL +

EZH2 +

FGFR3 +

FLT3 +

IGH +

IKZF1 +

KIT +

KMT2A +

KRAS +

MAF +

MAFB +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MYH11 +

NF1 +

NPM1 +

NRAS +

NRIP3 +

NUP214 +

PBX1 +

PHF6 +

PTPN11 +

RIT1 +

RPN1 +

RUNX1 +

RUNX1T1 +

SF3B1 +

SRSF2 +

STAG2 +

TCF3 +

TET2 +

TP53 +

U2AF1 +

WHSC1 +

ZRSR2 +

Disease Details

Synonyms
Therapy-Related MDS, t-MDS, Therapy Related Myelodysplastic Syndrome
Parent(s)
Therapy-Related Myeloid Neoplasm
OncoTree Name
Therapy-Related Myelodysplastic Syndrome
OncoTree Code
TMDS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.